Eli Lilly reminded Adverum Biotechnologies stockholders on December 1 that the tender window for its $11.25-per-share all-cash acquisition offer closes December 13 at 11:59 p.m. Eastern. The Redwood City-based clinical-stage gene therapy developer issued the reminder through D.F. King, the information agent managing the tender process. Lilly initially announced the acquisition in mid-October at a $11.25 cash price representing a 60% premium to Adverum's prior trading level, valuing the transaction at approximately $118 million on a fully diluted basis.
Adverum's core asset is ADVM-022, an intravitreal gene therapy candidate targeting wet age-related macular degeneration currently in Phase 2 trials. The platform delivers therapeutic genes directly into the eye via a single injection, positioning against the standard-of-care anti-VEGF injections that require dosing every four to eight weeks indefinitely. Lilly's diabetes and obesity franchise generated $15.4 billion in revenue through Q3 2024, but the company has been methodically building its ophthalmology pipeline through smaller bolt-on transactions rather than multi-billion dollar platform buys. The Adverum tender represents tactical acceleration: Lilly acquires late-stage clinical data, an established intravitreal delivery platform, and manufacturing relationships at a fraction of the cost of internal development timelines.
The December 13 deadline matters because tender offer mechanics require minimum participation thresholds before Lilly can proceed to the merger's second step without additional shareholder votes. Adverum's institutional ownership sits at approximately 72%, with Fidelity and BlackRock holding the largest blocks. The $11.25 price sits 11% below Adverum's 52-week high from August, when interim ADVM-022 data showed durability in a subset of patients, but 340% above the March 2024 low when cash runway concerns dominated the stock. The spread is tight—shares closed November 29 at $11.21, a 36-cent discount implying market confidence in deal closure but no competing bid premium.
Operators should track three specific milestones. First, D.F. King will announce preliminary tender participation by December 16, revealing whether Lilly clears the minimum threshold without extending the offer window. Second, the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee maintains a rolling calendar for gene therapy reviews; any ADVM-022 advisory committee scheduling between now and mid-2026 would signal Lilly's confidence in accelerating the filing timeline post-acquisition. Third, watch Lilly's Q4 2025 earnings call in early February for commentary on ophthalmology pipeline integration—management historically telegraphs development acceleration plans during the quarter following smaller acquisitions.
The $118 million purchase price allocates to Lilly's "capabilities and bolt-on" M&A bucket, not the transformational deal category. That distinction matters: Lilly has $6.8 billion in cash as of Q3 2024 and generates approximately $2 billion in quarterly free cash flow, leaving the ophthalmology budget largely untouched. The company's next Board meeting is scheduled for mid-January, the traditional window for approving additional tactical healthcare services or late-stage asset acquisitions before fiscal planning locks for the year.